...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta Haematologica >Engraftment efficacy of human hematopoietic stem cells transplanted into NOD/SCID mice using two methods: intra-bone marrow transplantation of hematopoietic stem cells and intravenous co-transplantation with mesenchymal stem cells.
【24h】

Engraftment efficacy of human hematopoietic stem cells transplanted into NOD/SCID mice using two methods: intra-bone marrow transplantation of hematopoietic stem cells and intravenous co-transplantation with mesenchymal stem cells.

机译：使用两种方法将人造血干细胞移植入NOD / SCID小鼠的植入效力：造血干细胞的骨髓内移植和间充质干细胞的静脉共移植。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Testicular lymphoma is a rare condition, so large scale prospective studies are difficult to conduct. Consensus regarding standard treatment is lacking. This study retrospectively reviewed 22 patients with testicular lymphoma. One patient with diffuse large B-cell lymphoma (DLBCL) was lost to follow-up after diagnosis. Two patients with Burkitt's lymphoma had poor outcomes regardless of treatment. Thus, we analyzed the clinical features, treatments, and outcomes of 19 patients with DLBCL. The median progression-free and overall survival was 28.3 and 36.3 months, respectively. A good response to treatment was a favorable prognostic factor. Because of the high relapse rate, the outcome is poor for testicular lymphoma. Therefore, long-term follow-up is strongly recommended.
机译：睾丸淋巴瘤是一种罕见的疾病，因此很难进行大规模的前瞻性研究。缺乏有关标准治疗的共识。这项研究回顾性回顾了22例睾丸淋巴瘤患者。一例弥漫性大B细胞淋巴瘤（DLBCL）患者在诊断后失访。无论采用何种治疗方法，两名Burkitt淋巴瘤患者的预后均较差。因此，我们分析了19例DLBCL患者的临床特征，治疗方法和预后。中位无进展生存期和总生存期分别为28.3和36.3个月。对治疗的良好反应是有利的预后因素。由于复发率高，睾丸淋巴瘤的预后较差。因此，强烈建议长期随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号